Industries > Pharma > Global Antibacterial Drugs Market 2017-2027

Global Antibacterial Drugs Market 2017-2027

Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others

PUBLISHED: 13 March 2017
PAGES: 304
PRODUCT CODE: PHA0175
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0175 Categories: , Tag:

The global antibacterial drugs market is expected to grow at a CAGR of 1.3% in the first half of the forecast period and a CAGR of 3.1% in the second half of the forecast period. The market is estimated at $41.76bn in 2016 and $44.54bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 304-page report you will receive 124 tables and 97 figures – all unavailable elsewhere.

The 304-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Antibacterial Drugs Market 2017-2027

Report Scope
Global Antibacterial Drugs Market forecasts from 2017-2027

• Revenue forecasts for the 6 leading submarkets from 2017-2027:
– Cephalosporins
– Penicillins
– Fluoroquinolones
– Macrolides
– Carbapenems
– Others

• Revenue forecasts for the 43 leading marketed antibacterial drugs from 2017-2027:
– Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
– Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
– Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
– Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
– Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
– Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin

• Revenue forecasts for the leading developed and emerging national and regional markets. Markets forecasted in this report are the following:
– The US
– The EU: France, Germany, Italy, Spain, the UK, and others
– Japan
– The BRIC countries: Brazil, Russia, India, China
– South Korea
– The Rest of the World

• Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market

• Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development – see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Antibacterial Drugs Market. You find data, trends and predictions.

Buy our report today Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Antibacterial Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Antibacterial Drugs Market 2017-2027


Latest Pharma news

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022

READ

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ